Methylation of TMEM176A, a key ERK Signaling Regulator, is a Novel Synthetic Lethality Marker of ATM Inhibitors in Human Lung Cancer

References

• Bray F , FerlayJ , SoerjomataramIet al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• Reck M , RabeKF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. New Engl. J. Med.377(9), 849–861 (2017).
   PubMed Web of Science ®Google Scholar
• Corrales L , RosellR , CardonaAFet al. Lung cancer in never smokers: the role of different risk factors other than tobacco smoking. Crit. Rev. Oncol. Hematol.148, 102895 (2020).
   PubMed Web of Science ®Google Scholar
• Brock MV , HookerCM , Ota-MachidaEet al. DNA methylation markers and early recurrence in stage I lung cancer. New Engl. J. Med.358(11), 1118–1128 (2008).
   PubMed Web of Science ®Google Scholar
• Guo M , RenJ , HouseMGet al. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin. Cancer Res.12(15), 4515–4522 (2006).
   PubMed Web of Science ®Google Scholar
• Yuan M , HuangLL , ChenJH , WuJ , XuQ. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal transduction and targeted therapy4, 61–75 (2019).
   PubMed Web of Science ®Google Scholar
• Guo M , LiuS , LuF. Gefitinib-sensitizing mutations in esophageal carcinoma. New Engl. J. Med.354(20), 2193–2194 (2006).
   PubMed Web of Science ®Google Scholar
• Herbst RS , MorgenszternD , BoshoffC. The biology and management of non-small cell lung cancer. Nature553(7689), 446–454 (2018).
   PubMed Web of Science ®Google Scholar
• Lim ZF , MaPC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J. Hematol. Oncol.12(1), 134 (2019).
   PubMed Web of Science ®Google Scholar
• Guo M , PengY , GaoAet al. Epigenetic heterogeneity in cancer. Biomark Res.7, 23 (2019).
   PubMed Web of Science ®Google Scholar
• Guo M , AlumkalJ , DrachovaTet al. CHFR methylation strongly correlates with methylation of DNA damage repair and apoptotic pathway genes in non-small cell lung cancer. Discov. Med.19(104), 151–158 (2015).
   PubMed Web of Science ®Google Scholar
• Yu Y , YanW , LiuXet al. DACT2 is frequently methylated in human gastric cancer and methylation of DACT2 activated Wnt signaling. Am. J. Cancer Res.4(6), 710–724 (2014).
   PubMed Web of Science ®Google Scholar
• Dolsten M , SøgaardM. Precision medicine: an approach to R&D for delivering superior medicines to patients. Clin. Transl. Med.1(1), 7 (2012).
   PubMedGoogle Scholar
• Gao A , GuoM. Epigenetic based synthetic lethal strategies in human cancers. Biomark Res.8, 44 (2020).
   PubMed Web of Science ®Google Scholar
• Hu Y , GuoM. Synthetic lethality strategies: beyond BRCA1/2 mutations in pancreatic cancer. Cancer Sci.111(9), 3111–3121 (2020).
   PubMed Web of Science ®Google Scholar
• Du W , GaoA , HermanJGet al. Methylation of NRN1 is a novel synthetic lethal marker of PI3K-Akt-mTOR and ATR inhibitors in esophageal cancer. Cancer Sci.112(7), 2870–2883 (2021).
   PubMed Web of Science ®Google Scholar
• Mclornan DP , ListA , MuftiGJ. Applying synthetic lethality for the selective targeting of cancer. New Engl. J. Med.371(18), 1725–1735 (2014).
   PubMed Web of Science ®Google Scholar
• Bryant HE , SchultzN , ThomasHDet al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature434(7035), 913–917 (2005).
   PubMed Web of Science ®Google Scholar
• Farmer H , MccabeN , LordCJet al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature434(7035), 917–921 (2005).
   PubMed Web of Science ®Google Scholar
• Hu Y , WenZ , LiuSet al. Ibrutinib suppresses intracellular mycobacterium tuberculosis growth by inducing macrophage autophagy. J. Infection80(6), e19–e26 (2020).
   PubMed Web of Science ®Google Scholar
• Gehrau R , MalufD , ArcherKet al. Molecular pathways differentiate hepatitis C virus (HCV) recurrence from acute cellular rejection in HCV liver recipients. Mole. Med. (Cambridge, Mass.)17(7–8), 824–833 (2011).
   PubMed Web of Science ®Google Scholar
• Nakajima H , TakenakaM , KaimoriJYet al. Gene expression profile of renal proximal tubules regulated by proteinuria. Kidney Int.61(5), 1577–1587 (2002).
   PubMed Web of Science ®Google Scholar
• Zuccolo J , DengL , UnruhTLet al. Expression of MS4A and TMEM176 genes in human B lymphocytes. Front. Immunol.4, 195 (2013).
   PubMed Web of Science ®Google Scholar
• Condamine T , LeTexier L , HowieDet al. Tmem176B and Tmem176A are associated with the immature state of dendritic cells. J. Leukoc. Biol.88(3), 507–515 (2010).
   PubMed Web of Science ®Google Scholar
• Grunin M , Hagbi-LeviS , RinskyBet al. Transcriptome analysis on monocytes from patients with neovascular age-related macular degeneration. Sci. Rep.6, 29046 (2016).
   PubMed Web of Science ®Google Scholar
• Gao D , HanY , YangYet al. Methylation of TMEM176A is an independent prognostic marker and is involved in human colorectal cancer development. Epigenetics12(7), 575–583 (2017).
   PubMed Web of Science ®Google Scholar
• Li H , ZhangM , LinghuEet al. Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma. Clin. Epigenetics10(1), 137 (2018).
   PubMedGoogle Scholar
• Wang Y , ZhangY , HermanJG , LinghuE , GuoM. Epigenetic silencing of TMEM176A promotes esophageal squamous cell cancer development. Oncotarget.8(41), 70035–70048 (2017).
   PubMedGoogle Scholar
• Guo M , AkiyamaY , HouseMGet al. Hypermethylation of the GATA genes in lung cancer. Clin. Cancer Res.10(23), 7917–7924 (2004).
   PubMed Web of Science ®Google Scholar
• Guo M , HouseMG , SuzukiHet al. Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer. Int. J. Cancer121(6), 1219–1226 (2007).
   PubMed Web of Science ®Google Scholar
• Liu X , ZhangX , ZhanQet al. CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer. Cancer Biol. Ther.13(12), 1152–1157 (2012).
   PubMed Web of Science ®Google Scholar
• Morris EJ , JhaS , RestainoCRet al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov.3(7), 742–750 (2013).
   PubMed Web of Science ®Google Scholar
• Zheng R , GaoD , HeTet al. Methylation of DIRAS1 promotes colorectal cancer progression and may serve as a marker for poor prognosis. Clin. Epigenetics9, 50 (2017).
   PubMed Web of Science ®Google Scholar
• Yan W , WuK , HermanJGet al. Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer. Epigenetics8(12), 1373–1383 (2013).
   PubMed Web of Science ®Google Scholar
• Jia Y , YangY , LiuSet al. SOX17 antagonizes WNT/β-catenin signaling pathway in hepatocellular carcinoma. Epigenetics5(8), 743–749 (2010).
   PubMed Web of Science ®Google Scholar
• Cui YGD , LinghuE , ZhanQet al. Epigenetic changes and functional study of HOXA11 in human gastric cancer. Epigenomics7(2), 201–213 (2015).
   PubMed Web of Science ®Google Scholar
• Brown JS , O’CarriganB , JacksonSP , YapTA. Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov.7(1), 20–37 (2017).
   PubMed Web of Science ®Google Scholar
• Yang MC , LinRW , HuangSBet al. Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53. Cell Cycle15(3), 394–402 (2016).
   PubMed Web of Science ®Google Scholar
• Hegedűs C , BorosG , FidrusEet al. PARP1 inhibition augments UVB-mediated mitochondrial changes–impications for UV-induced DNA repair and photocarcinogenesis. Cancers12(1), (2019).
   PubMed Web of Science ®Google Scholar
• Golding SE , RosenbergE , NeillSet al. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res.67(3), 1046–1053 (2007).
   PubMed Web of Science ®Google Scholar
• Riegman PH , BurgartLJ , WangKKet al. Allelic imbalance of 7q32.3-q36.1 during tumorigenesis in Barrett’s esophagus. Cancer Res.62(5), 1531–1533 (2002).
   PubMed Web of Science ®Google Scholar
• Kimmel RR , ZhaoLP , NguyenDet al. Microarray comparative genomic hybridization reveals genome-wide patterns of DNA gains and losses in post-Chernobyl thyroid cancer. Radiat. Res.166(3), 519–531 (2006).
   PubMed Web of Science ®Google Scholar
• Liu Z , AnH , SongPet al. Potential targets of TMEM176A in the growth of glioblastoma cells. OncoTarget. Ther.11, 7763–7775 (2018).
   PubMed Web of Science ®Google Scholar
• Drujont L , LemoineA , MoreauAet al. RORgammat+ cells selectively express redundant cation channels linked to the Golgi apparatus. Sci. Rep.6, 23682 (2016).
   PubMed Web of Science ®Google Scholar
• Yan W , HermanJG , GuoM. Epigenome-based personalized medicine in human cancer. Epigenomics8(1), 119–133 (2016).
   PubMed Web of Science ®Google Scholar
• Pfister SX , AshworthA. Marked for death: targeting epigenetic changes in cancer. Nat. Rev. Drug Discov.16(4), 241–263 (2017).
   PubMed Web of Science ®Google Scholar
• Lord CJ , AshworthA. BRCAness revisited. Nat. Rev. Cancer16(2), 110–120 (2016).
   PubMed Web of Science ®Google Scholar
• Zhong Z , VirshupDM. Wnt signaling and drug resistance in cancer. Mol. Pharmacol.97(2), 72–89 (2020).
   PubMed Web of Science ®Google Scholar
• Huang TT , LampertEJ , CootsC , LeeJM. Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer. Cancer Treatment Rev.86, 102021 (2020).
   PubMed Web of Science ®Google Scholar
• Morrison C , SonodaE , TakaoN et al. The controlling role of ATM in homologous recombinational repair of DNA damage. The EMBO J.19(3), 463–471 (2000).
   PubMed Web of Science ®Google Scholar